Guardian Pharmacy Services, Inc. GRDN

Consumer discretionary SIC 5912 - Retail-Drug Stores and Proprietary Stores NYSE

We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We emphasize high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities ("ALFs"), and behavioral health facilities and group homes (collectively "BHFs"). More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs, which are our target markets, while the remainder has been generated primarily from residents of skilled nursing facilities ("SNFs"). Additionally, our robust suite of capabilities enables us to serve residents in all types of LTCFs. We are a trusted partner to residents, LTCFs and health plan payors because we help reduce errors in drug administration, manage and ensure adherence to drug regimens, and lower overall healthcare costs. As of December 31, 2025, our 61 pharmacies, 54 of which are full-service, served approximately 205,000 residents in approximately 8,400 LTCFs across 38 states.

Last close 40.77 2026-09-04
Market cap
52-week range 23.14 - 47.02

Valuation FY2025 figures against the last close

P/S
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
Revenue $1.45B$1.23B
Cost of revenue $1.16B$984.0M
Gross profit $292.7M$244.4M
SG&A $220.0M$307.3M
Operating income $72.7M-$62.9M
Interest expense $665.0K$3.3M
Pre-tax income $73.4M-$66.5M
Income tax $24.5M$4.6M
Net income $49.2M-$110.0M

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $65.6M$4.7M$752.0K
Receivables $101.6M$97.2M
Inventory $43.4M$40.5M
Total current assets $221.6M$152.0M
Property, plant and equipment $55.5M$49.9M
Goodwill $79.7M$69.3M
Other intangibles $18.5M$14.9M
Total assets $412.7M$320.8M
Accounts payable $116.2M$102.4M
Total current liabilities $160.7M$144.1M
Long-term debt $0$0
Total liabilities $194.7M$170.8M
Retained earnings $66.3M$17.1M
Total equity $217.9M$150.0M$59.9M

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow $100.3M$58.0M
Depreciation and amortisation $22.3M$19.8M
Stock-based compensation $13.8M$131.5M
Capital expenditure $13.4M$14.7M
Investing cash flow -$32.2M-$30.4M
Financing cash flow -$7.1M-$23.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-102172.

Others in SIC 5912

TickerCompanyMarket capP/ERevenue growth
CVS CVS HEALTH Corp $123.73B 69.6x 7.8%
PETS PETMED EXPRESS INC $39.2M -21.1%
YI 111, Inc. -9.0%
RDGT Ridgetech Inc. 10.2%